In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Oncocyte Corporation (NASDAQ: OCX) closed at $2.30 down -3.77% from its previous closing price of $2.39. In other words, the price has decreased by -$3.77 from its previous closing price. On the day, 0.61 million shares were traded. OCX stock price reached its highest trading level at $2.44 during the session, while it also had its lowest trading level at $1.98.
Ratios:
For a deeper understanding of Oncocyte Corporation’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.47 and its Current Ratio is at 0.49. In the meantime, Its Debt-to-Equity ratio is 0.41 whereas as Long-Term Debt/Eq ratio is at 0.28.
On January 07, 2022, Stephens started tracking the stock assigning a Overweight rating and target price of $3.10.Stephens initiated its Overweight rating on January 07, 2022, with a $3.10 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 02 ’24 when James Andrea S. bought 33,670 shares for $2.97 per share. The transaction valued at 100,000 led to the insider holds 33,670 shares of the business.
BROADWOOD PARTNERS, L.P. bought 1,315,339 shares of OCX for $3,877,619 on Oct 02 ’24. The 10% Owner now owns 6,244,405 shares after completing the transaction at $2.95 per share. On Apr 11 ’24, another insider, BROADWOOD PARTNERS, L.P., who serves as the 10% Owner of the company, bought 2,420,000 shares for $2.92 each. As a result, the insider paid 7,057,688 and bolstered with 4,929,066 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCX now has a Market Capitalization of 40236200 and an Enterprise Value of 32170200. For the stock, the TTM Price-to-Sale (P/S) ratio is 54.54 while its Price-to-Book (P/B) ratio in mrq is 3.17. Its current Enterprise Value per Revenue stands at 45.374 whereas that against EBITDA is -1.492.
Stock Price History:
Over the past 52 weeks, OCX has reached a high of $3.94, while it has fallen to a 52-week low of $2.00. The 50-Day Moving Average of the stock is -19.96%, while the 200-Day Moving Average is calculated to be -21.34%.
Shares Statistics:
For the past three months, OCX has traded an average of 49.39K shares per day and 108240 over the past ten days. A total of 16.84M shares are outstanding, with a floating share count of 13.99M. Insiders hold about 16.92% of the company’s shares, while institutions hold 51.24% stake in the company. Shares short for OCX as of 1731628800 were 225559 with a Short Ratio of 4.57, compared to 1728950400 on 189327. Therefore, it implies a Short% of Shares Outstanding of 225559 and a Short% of Float of 1.94.
